Should I take a statin for a high ApoB?
On this page
This page lays out both sides so you can have a better conversation with your doctor. It never tells you to start, stop or change a medicine. If you take one, your prescriber decides any change.
It depends on your risk more than on your number. The 2026 US guideline recommends a statin for people who’ve had a heart attack or stroke, who have an ApoB of 140 or more or an LDL of 190 or more, who have diabetes between 40 and 75, or whose 10-year risk is 5% or more. For everyone else it’s a choice to make with your doctor. Statins lower ApoB about a third on average, the side effects are smaller than their reputation, and the benefit depends on how high your risk is to begin with.
What we’d do
Know three things before the appointment: your ApoB, your LDL, and your 10-year risk band from the PREVENT calculator. If you want to and can, start the natural way, with food. Bring the questions at the end of this page. If you already take a statin, keep taking it while you ask them.
Why it turns into an argument
Online, statins get two stories. In one they’re poison that causes muscle pain and diabetes. In the other everyone over 40 should take one. Both stories leave out your risk, which is the thing that sets how much a statin can do for you. A pill that cuts risk by a fifth does a lot for someone at high risk and very little for someone at low risk.
The case for
It lowers the count a lot. Across 11 trials of LDL-lowering medicine, ApoB fell 33% on average, against 42% for LDL. From an ApoB of 120 that’s about 40 points, several times what the best food changes did in trials. Adding ezetimibe on top took ApoB down a further 15% in one trial, and the injected PCSK9 medicines more than 40%.
Lower counts mean fewer heart attacks. Across 26 trials and about 170,000 people, each 1 mmol/L (39 mg/dL) of LDL that statins took off cut heart attacks, strokes and artery procedures by 22%. The genes say the same about ApoB itself. In 654,783 people, being born with an ApoB 10 points lower went with about 23% lower odds of heart disease, whichever gene did it.
The higher your risk, the more it buys. The same relative cut takes far more events off a high risk than a low one, which is why the guideline puts the strongest recommendations on people with heart disease, an ApoB of 140 or more, or diabetes.
The case against
At low risk the gain is small. The guideline doesn’t recommend a statin for most people under 3% risk. For them it recommends healthy habits, and saves medicine for an LDL of 160 to 189 or a high 30-year risk.
Some people get muscle aches, though far fewer than blame the statin. In blinded trials of about 124,000 people, 27.1% on a statin and 26.6% on a placebo reported muscle pain or weakness. The researchers worked out that only about 1 in 15 of those reports was due to the statin, and the small excess came mostly in the first year. Higher doses carry more risk of muscle symptoms, the guideline says.
Blood sugar can rise a little. In the same trials, new diabetes diagnoses were 10% more common on a low or moderate dose and 36% more common on a high dose. About 62% of the new cases were in people whose blood sugar was already in the top quarter, near the line. If diabetes does develop, the guideline recommends staying on the statin, with the overall benefit in mind.
It’s a pill every day, maybe for decades, and ApoB falls less than LDL on it, so your LDL can reach its goal while your ApoB doesn’t. ApoB on a statin explains what happens then.
Who the guideline offers it to
| Who | What the 2026 guideline says |
|---|---|
| A heart attack, stroke, stent or bypass | A high-intensity statin, started or continued, up to age 75 (class 1) |
| An LDL of 190 or more, or an ApoB of 140 or more | Check for other causes, then a statin at the highest dose you tolerate (class 1) |
| Diabetes, aged 40 to 75 | A moderate statin, whatever your 10-year risk (class 1) |
| 10-year risk of 10% or more | A high-intensity statin if treatment starts (class 1) |
| 10-year risk of 5 to under 10% | At least a moderate statin is recommended (class 1) |
| 10-year risk of 3 to under 5% | A moderate statin if you and your doctor decide to start (class 2a) |
| Under 3%, aged 30 to 59 | Healthy habits, with a moderate statin reasonable only for an LDL of 160 to 189 or a high 30-year risk (class 2a) |
Before any of these, the guideline recommends a talk with your doctor about the benefits and risks (class 1), and healthy habits in every group. Once you’re on treatment and your LDL is at its goal, it says measuring ApoB is reasonable to decide whether to do more.
Like opening a drain wider
Your liver pulls particles out of the blood through receptors, like water going down a drain. Statins slow the liver’s own cholesterol making, so it puts more receptors on its surface and opens the drain wider. Food changes do some of the same thing more gently. Saturated fat narrows the drain, which is why cutting it helps. Can I lower ApoB without medication? sizes the food side, and How do I lower ApoB naturally? puts it in weeks.
Questions to bring
- What’s my 10-year risk on the PREVENT calculator, and which band does that put me in?
- What’s my ApoB goal at that risk, and how far am I from it?
- How much would a statin likely lower my ApoB, and how much would food changes?
- Is there anything in my family history, Lp(a) or other results that changes my risk?
- If I try food first, when should we retest, and what result would change the plan?
- If I start, which dose, and what should I do if I get muscle aches?
- If I’m already on one and my LDL is at goal, is my ApoB at goal too?
What nobody knows yet
No trial has treated one group to an ApoB goal and another to an LDL goal and counted heart attacks. Most statin trials ran about five years, so the evidence for people who are young and at low risk, who might take one for decades, comes from the gene studies more than from trials. The 2026 guideline page has the latest, including a computer model that favored treating to ApoB.
Your prescriber decides whether to start, change or stop a medicine. Never stop one on your own.
8 sources
- Blumenthal RS, Morris PB, Gaudino M and others, 2026 ACC/AHA guideline on the management of dyslipidemia, JACC, 2026doi.org
- The same guideline, full text, Circulation, 2026api.iscpcardio.org
- Soffer DE, Marston NA, Maki KC and others, Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association, Journal of Clinical Lipidology, 2024pmc.ncbi.nlm.nih.gov
- Cholesterol Treatment Trialists' Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 2010pubmed.ncbi.nlm.nih.gov
- Cholesterol Treatment Trialists' Collaboration, Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials, Lancet, 2022pmc.ncbi.nlm.nih.gov
- Cholesterol Treatment Trialists' Collaboration, Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials, Lancet Diabetes and Endocrinology, 2024pubmed.ncbi.nlm.nih.gov
- Fernandez ML, West KL, Mechanisms by which dietary fatty acids modulate plasma lipids, Journal of Nutrition, 2005pubmed.ncbi.nlm.nih.gov
- Ference BA and others, Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease, JAMA, 2019pmc.ncbi.nlm.nih.gov